Corbus Pharmaceuticals Holdings, Inc.
CRBP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $1 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $1 | $0 | $1 | $2 |
| Gross Profit | -$1 | $0 | -$1 | -$1 |
| % Margin | – | – | – | -85.9% |
| R&D Expenses | $32 | $31 | $16 | $36 |
| G&A Expenses | $16 | $14 | $19 | $20 |
| SG&A Expenses | $16 | $14 | $19 | $20 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$1 | $0 | -$1 | -$2 |
| Operating Expenses | $48 | $45 | $33 | $55 |
| Operating Income | -$49 | -$45 | -$35 | -$56 |
| % Margin | – | – | – | -6,350.1% |
| Other Income/Exp. Net | $9 | $0 | -$8 | $10 |
| Pre-Tax Income | -$40 | -$45 | -$42 | -$46 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$40 | -$45 | -$56 | -$46 |
| % Margin | – | – | – | -5,166.4% |
| EPS | -3.68 | -10.31 | -10.15 | -11.11 |
| % Growth | 64.3% | -1.6% | 8.6% | – |
| EPS Diluted | -3.68 | -10.31 | -10.15 | -11.11 |
| Weighted Avg Shares Out | 11 | 4 | 4 | 4 |
| Weighted Avg Shares Out Dil | 11 | 4 | 4 | 4 |
| Supplemental Information | – | – | – | – |
| Interest Income | $6 | $0 | $0 | $0 |
| Interest Expense | $2 | $3 | $2 | $2 |
| Depreciation & Amortization | $1 | $1 | $1 | $2 |
| EBITDA | -$38 | -$40 | -$39 | -$54 |
| % Margin | – | – | – | -6,164.2% |